Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Medifast launches Trilivy, replacing its Optavia brand
TD Cowen Reiterates Buy Rating on Legend Biotech Corp. (LEGN), PT $62, 'We Like The Profile At These Levels'
May 13, 2025 4:38 PM EDTTD Cowen analyst Yaron Werber reiterated a Buy rating and $62.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst comments "Our Take: Carvykti Continues Solid Ramp, With Growth Likely Weighted Towards H2:25 We Like The Profile At These Levels We like the risk/reward of the stock at these levels given a solid sales ramp for Carvykti on the heels of strong demand, especially in... More
